Editorial: Recent advances in fibrosis assessment for metabolic dysfunction-associated fatty liver disease-Authors' reply
- PMID: 37632278
- DOI: 10.1111/apt.17660
Editorial: Recent advances in fibrosis assessment for metabolic dysfunction-associated fatty liver disease-Authors' reply
Comment on
-
AutoFibroNet: A deep learning and multi-photon microscopy-derived automated network for liver fibrosis quantification in MAFLD.Aliment Pharmacol Ther. 2023 Sep;58(6):573-584. doi: 10.1111/apt.17635. Epub 2023 Jul 4. Aliment Pharmacol Ther. 2023. PMID: 37403450
-
Recent advances in fibrosis assessment for metabolic dysfunction-associated fatty liver disease.Aliment Pharmacol Ther. 2023 Sep;58(6):636-637. doi: 10.1111/apt.17651. Aliment Pharmacol Ther. 2023. PMID: 37632279 No abstract available.
References
REFERENCES
-
- Jeffrey AW, Adams LA. Editorial: recent advances in fibrosis assessment for metabolic dysfunction associated fatty liver disease. Aliment Pharmacol Ther. 2023;58:636-637.
-
- Zhan H, Chen S, Gao F, Wang G, Chen SD, Xi G, et al. AutoFibroNet: a deep learning and multi-photon microscopy-derived automated network for liver fibrosis quantification in MAFLD. Aliment Pharmacol Ther. 2023;58:573-584.
-
- Jahn SW, Plass M, Moinfar F. Digital pathology: advantages, limitations and emerging perspectives. J Clin Med. 2020;9(11):3697.
-
- Campanella G, Hanna MG, Geneslaw L, Miraflor A, Werneck Krauss Silva V, Busam KJ, et al. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nat Med. 2019;25(8):1301-1309.
-
- Anstee QM, Lucas KJ, Francque S, Abdelmalek MF, Sanyal AJ, Ratziu V, et al. Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: results from the Phase 2b TANDEM study. Hepatology. 2023. https://doi.org/10.1097/HEP.0000000000000439
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Medical